News
AKYA
1.290
0.00%
0.000
Carlsmed Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary Amid Leadership Expansion
Reuters · 09/29/2025 13:01
Quanterix Corporation Issues Amendment to Financial Report Following Merger with Akoya Biosciences
Reuters · 09/23/2025 20:07
Quanterix Q2 revenue falls 29%, net loss widens
Reuters · 08/07/2025 21:00
Quanterix Reports Q2 Net Loss of $30M, Alzheimer's Diagnostics Revenues More Than Tripled Year-Over-Year
Reuters · 08/07/2025 20:26
Quanterix Corporation Announces Workforce Reduction Plan to Save $18 Million Annually Following Akoya Biosciences Acquisition
Reuters · 07/24/2025 20:31
Quanterix Corporation Announces Executive Terminations at Akoya Biosciences in Cost-Saving Reorganization Plan
Reuters · 07/18/2025 20:31
Quanterix Corporation Announces Inducement Grants of Restricted Stock Units to New Employees Following Akoya Biosciences Acquisition
Reuters · 07/11/2025 21:00
*News On Akoya Biosciences Inc. (AKYA) Now Under QTRX
Dow Jones · 07/08/2025 21:08
Akoya Biosciences Completes Merger and Nasdaq Delisting
TipRanks · 07/08/2025 13:43
Akoya Biosciences Inc. Finalizes Merger with Quanterix, Terminates Key Agreements
Reuters · 07/08/2025 13:24
Quanterix Corporation Announces New Board Members as Mendel and Lai-Goldman Join Leadership Team Following Akoya Acquisition
Reuters · 07/08/2025 13:07
Akoya Biosciences Inc. Conducted Special Stockholders Meeting
Reuters · 07/07/2025 20:05
Weekly Report: what happened at AKYA last week (0630-0704)?
Weekly Report · 07/07/2025 09:00
Weekly Report: what happened at AKYA last week (0623-0627)?
Weekly Report · 06/30/2025 09:01
Weekly Report: what happened at AKYA last week (0616-0620)?
Weekly Report · 06/23/2025 09:00
Weekly Report: what happened at AKYA last week (0609-0613)?
Weekly Report · 06/16/2025 09:01
Weekly Report: what happened at AKYA last week (0602-0606)?
Weekly Report · 06/09/2025 09:01
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 06/03/2025 17:06
Akoya Biosciences price target lowered to $1.14 from $3 at Morgan Stanley
TipRanks · 06/02/2025 11:00
AKOYA BIOSCIENCES, INC. <AKYA.O>: MORGAN STANLEY CUTS TARGET PRICE TO $1.14 FROM $3.00
Reuters · 06/02/2025 10:28
More
Webull provides a variety of real-time AKYA stock news. You can receive the latest news about Akoya Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About AKYA
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. It offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays.